Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
12/05/2016 12/06/2016 12/07/2016 12/08/2016 12/09/2016 Date
41.82(c) 42.98(c) 43.64(c) 43.98(c) 44.965(c) Last
131 124 179 319 181 368 166 292 176 282 Volume
+1.59% +2.77% +1.54% +0.78% +2.24% Change
More quotes
Financials (€)
Sales 2016 49,9 M
EBIT 2016 -64,5 M
Net income 2016 -52,9 M
Finance 2016 238 M
Yield 2016 -
Sales 2017 51,4 M
EBIT 2017 -67,8 M
Net income 2017 -49,2 M
Finance 2017 213 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 21,5x
EV / Sales2017 21,4x
Capitalization 1 311 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
12/06 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in..
12/06 MORPHOSYS : Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at A..
12/06 MORPHOSYS PRESENTS UPDATED CLINICAL :
11/29 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/28 MORPHOSYS : Announces That Its Licensee Janssen Has Submitted a Marketing Author..
11/25 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/22 CORRECTION OF A RELEASE FROM 21.11.2 : 05 CET - MorphoSys AG: Publication pursua..
11/21 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/21 MORPHOSYS AG : Notification of managers`transactions according to article 19 MAR
11/21 MORPHOSYS AG : Notification of managers`transactions according to article 19 MAR
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/22 Morphosys Ag (MPSYY) Investor Presentation - Slideshow
11/08 MorphoSys' (MPSYF) CEO Simon Moroney on Q3 2016 Results - Earnings Call Trans..
11/07 MorphoSys AG reports 9M results
10/04 Allergan Shows It Has Stomach For More GI Dealmaking
09/21 MorphoSys (MPSYY) Presents at Bank of America Merrill Lynch 2016 Global Healt..
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 62,9 €
Spread / Average Target 40%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-22.00%1 384
QUINTILES IMS HOLDINGS..14.10%19 286
INCYTE CORPORATION-7.21%18 957
CELLTRION, INC.--.--%9 997
LONZA GROUP AG9.20%9 261
SEATTLE GENETICS, INC.44.54%9 183
More Results